{"id":"NCT00176202","sponsor":"University of Illinois at Chicago","briefTitle":"Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar","officialTitle":"Controlled Trial of Risperidone and Divalproex Sodium With MRI Assessment of Affected Circuitry in Pre and Post Treatment in Pediatric Bipolar","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-04","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2005-09-15","resultsPosted":"2015-11-05","lastUpdate":"2015-11-05"},"enrollment":65,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Divalproex Sodium","otherNames":["antiepileptic","valproic acid"]},{"type":"DRUG","name":"risperidone","otherNames":["antipsychotic","risperdal"]}],"arms":[{"label":"Risperidone","type":"ACTIVE_COMPARATOR"},{"label":"Divalproex sodium","type":"ACTIVE_COMPARATOR"}],"summary":"The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.","primaryOutcome":{"measure":"Young Mania Rating Scale (YMRS)","timeFrame":"Six week study with assessment at baseline and end of the study (at the end of 6 weeks or earlier if they ended the study before 6 week end point).","effectByArm":[{"arm":"Divalproex","deltaMin":25.09,"sd":7.51},{"arm":"Risperidone","deltaMin":30.59,"sd":7.04}],"pValues":[{"comp":"OG000","p":"<0.01"},{"comp":"OG001","p":"<0.01"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["22265362"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Increased appetite","stomach discomfort","sleepiness","fatigue/tiredness","Irritable/agitated"]}}